

Since 2008, ISMP has maintained a list of drug name pairs or larger groupings with recommended, uppercase and bolded tall man (mixed case) letters to help draw attention to the dissimilarities in look-alike drug names. The list includes mostly generic-generic drug name pairs, although a few brand-brand or brand-generic name pairs are also included. The US Food and Drug Administration (FDA) list of drug names with recommended tall man letters was initiated in 2001 with the agency's Name Differentiation Project (www.ismp.org/ext/1072).

While numerous studies between 2000 and 2021 have demonstrated the ability of tall man letters alone or in conjunction with other text enhancements to improve the accuracy of drug name perception and reduce errors due to drug name similarity, 1-12 some studies have suggested that the evidence is conflicting or the strategy is ineffective. 13-16 The evidence has been mixed due in large part to methodological differences and significant study limitations. However, because gaps still exist in our full understanding of the role of tall man lettering in the clinical setting, ISMP is participating in a 4-year Northwestern University (Chicago) research project, led by Bruce L. Lambert, PhD, and funded by FDA, to assess the comparative effectiveness of various methods of drug name text enhancements and the ability of tall man lettering to reduce errors during drug selection. Meanwhile, there is sufficient evidence to suggest that the simple and straightforward technique of using tall man letters is worth implementing as one among numerous strategies to mitigate the risk of errors due to similar drug names.

To await irrefutable, scientific proof of effectiveness minimizes and undervalues the study findings and anecdotal evidence available today¹⁷ that support this important risk-reduction strategy. As such, the use of tall man letters has been endorsed by ISMP, The Joint Commission (TJC) (recommended but not required), FDA

(as part of its Name Differentiation Project), as well as other national and international organizations, including the World Health Organization (WHO) and the International Medication Safety Network (IMSN).18

Table 1 (page 2) provides an alphabetized list of FDA-approved established drug names with recommended tall man letters.

Table 2 (starting on page 3) provides an alphabetized list of additional drug names with recommendations from ISMP regarding the use and placement of tall man letters. This is not an official list approved by FDA. It is intended for voluntary use by healthcare practitioners, drug information vendors, and medication technology vendors. Any product label changes by manufacturers require FDA approval.

To promote standardization regarding which letters to present in uppercase/bold, ISMP follows a tested methodology whenever possible called the CD3 rule.19 The methodology suggests working from the left of the drug name first by capitalizing all the characters to the right once 2 or more dissimilar letters are encountered, and then, working from the right, returning 2 or more letters common to both words to lowercase letters. When the rule cannot be applied because there are no common letters on the right side of the name, the methodology suggests capitalizing the central part of the word only. When application of this rule fails to lead to the best tall man lettering option (e.g., makes names appear too similar, makes names hard to read based on pronunciation), an alternative option is considered.

To promote consistency, ISMP suggests following the bolded, tall man lettering schemes provided by FDA and ISMP for the drug name pairs listed in **Tables 1** (page 2) and 2 (starting on page 3).

Table 1. FDA-Approved List of Generic Drug	Names with Tall Man (Mixed Case) Letters
Drug Name With Tall Man Letters	Confused With
aceta ZOLAMIDE	aceto HEXAMIDE *
aceto HEXAMIDE *	aceta ZOLAMIDE
bu PROP ion	bus PIR one
bus PIR one	bu PROP ion
CARBO platin	CIS platin
chlorpro MAZINE	chlorpro PAMIDE
chlorpro PAMIDE	chlorpro MAZINE
CIS platin	CARBO platin
clomi PHENE	clomi PRAMINE
clomi PRAMINE	clomi PHENE
cyclo SERINE	cyclo SPORINE
cyclo SPORINE	cyclo SERINE
DAUNO rubicin	DOXO rubicin
dimenhy DRINATE	diphenhydr AMINE
diphenhydr AMINE	dimenhy DRINATE
DOBUT amine	DOP amine
DOP amine	DOBUT amine
DOXO rubicin	DAUNO rubicin
glipi ZIDE	gly BURIDE
gly BURIDE	glipi ZIDE
hydr ALAZINE	HYDRO morphone — hydr OXY zine
HYDRO morphone	hydr ALAZINE — hydr OXY zine
hydr OXY zine	hydr ALAZINE — HYDRO morphone
medroxy PROGESTER one	methyl PREDNIS olone — methyl TESTOSTER one
methyl PREDNIS olone	medroxy PROGESTER one — methyl TESTOSTER one
methyl TESTOSTER one	methyl PREDNIS olone — medroxy PROGESTER one
mig ALA stat	mig LU stat
mig LU stat	mig ALA stat
mito XANTRONE	Not specified
ni CAR dipine	NIFE dipine
NIFE dipine	ni CAR dipine
predniso LONE	predni SONE
predni SONE	predniso LONE
risperi DONE	r OPINIR ole
r OPINIR ole	risperi DONE
sulf ADIAZINE	sulfi SOXAZOLE *
sulfi SOXAZOLE *	sulf ADIAZINE
TOLAZ amide	TOLBUTamide*
TOLBUTamide*	TOLAZ amide
tra MAD ol	tra ZOD one
tra ZOD one	tra MAD ol
vin BLAS tine	vin CRIS tine
vin CRIS tine	vin BLAS tine

^{*} These drugs have been discontinued and are not marketed in the United States.



Drug Name With Tall Man Letters	Confused With
AL fentanil	fenta NYL — SUF entanil
ALPRAZ olam	clonaze PAM — LOR azepam
a MIL oride	am LODIP ine
am LODIP ine	a MIL oride
ARIP iprazole	RABE prazole
aza CITID ine	aza THIO prine
aza THIO prine	aza CITID ine
BUP ivacaine	ROP ivacaine
car BAM azepine	OX carbazepine
CARBO platin [†]	CIS platin [†]
ce FAZ olin	cefo TE tan — cef OX itin — cef TAZ idime — cef TRIAX one
cefo TE tan	ce FAZ olin — cef OX itin — cef TAZ idime — cef TRIAX one
cef 0X itin	ce FAZ olin — cefo TE tan — cef TAZ idime — cef TRIAX one
cef TAZ idime	ce FAZ olin — cefo TE tan — cef OX itin — cef TRIAX one
cef TRIAX one	ce FAZ olin — cefo TE tan — cef OX itin — cef TAZ idime
Cele BREX ‡	Cele XA [‡]
Cele XA ‡	Cele BREX [‡]
chlordiaze POXIDE	chlorpro MAZINE †
chlorpro MAZINE †	chlordiaze POXIDE
CIS platin [†]	CARBO platin [†]
clo BAZ am	clonaze PAM
clonaze PAM	ALPRAZolam — cloBAZam — cloNIDine — cloZAPine — LORazepar
clo NID ine	clonaze PAM — clo ZAP ine — Klono PIN ‡
clo ZAP ine	clonaze PAM — clo NID ine
cyclo PHOS phamide	cyclo SERINE † — cyclo SPORINE †
cyclo SERINE †	cyclo PHOS phamide — cyclo SPORINE †
cyclo SPORINE †	cyclo PHOS phamide — cyclo SERINE †
DACTIN omycin	DAPTO mycin
DAPTO mycin	DACTIN omycin
DEPO -Medrol [‡]	SOLU -Medrol [‡]
dex AMETH asone	dexmede TOMID ine
dexmede TOMID ine	dex AMETH asone
diaze PAM	dil TIAZ em
dil TIAZ em	diaze PAM
DOCE taxel	PACL itaxel
DOXO rubicin [†]	IDA rubicin
dro NAB inol	dro PER idol

continued on page 4 >

[‡] Brand names always start with an uppercase letter. Some brand names incorporate tall man letters in initial characters and may not be readily recognized as brand names. A double dagger follows all brand names on the ISMP list.



^{*} These drugs have been discontinued and are not marketed in the United States.

 $^{^{\}dagger}$ These drug names are also on the FDA list.

Drug Name With Tall Man Letters	Confused With
dro PER idol	dro NAB inol
DUL oxetine	FLUoxetine — PARoxetine
e PHED rine	EPINEPH rine
EPINEPH rine	e PHED rine
epi RUB icin	eri BUL in
eri BUL in	epi RUB icin
fenta NYL	AL fentanil — SUF entanil
flavox ATE	fluvoxa MINE
FLU oxetine	DUL oxetine — PAR oxetine
flu PHENAZ ine	fluvoxa MINE
fluvoxa MINE	flavox ATE — flu PHENAZ ine
guai FEN esin	guan FACINE
guan FACINE	guai FEN esin
Huma LOG ‡	Humu LIN ‡
Humu LIN ‡	Huma LOG [‡]
hydr ALAZINE †	hydro CHLORO thiazide — hydr OXY zine [†]
hydro CHLORO thiazide	hydr ALAZINE † — hydr OXY zine†
HYDRO codone	oxy CODONE
HYDRO morphone [†]	morphine — oxy MOR phone
HYDROXY progesterone	medroxy PROGESTER one [†]
hydr OXY zine [†]	$hydr \textbf{ALAZINE}^{\dagger} - hydro \textbf{CHLORO} thiazide$
IDA rubicin	DOXO rubicin [†] — idaru CIZU mab
idaru CIZU mab	IDA rubicin
in FLIX imab	ri TUX imab
ISO tretinoin	tretinoin
Klono PIN ‡	clo NID ine
La MIC tal [‡]	Lam isiL ‡
Lam iSiL ‡	La MIC tal [‡]
lami VUD ine	lamo TRI gine
lamo TRI gine	lami VUD ine
lev ETIRA cetam	lev OCARN itine — levo FLOX acin
lev OCARN itine	lev ETIRA cetam
levo FLOX acin	lev ETIRA cetam
LEVO leucovorin	leucovorin
LOR azepam	ALPRAZolam — clonazePAM
medroxy PROGESTER one [†]	HYDROXY progesterone

continued on page 5 >

[‡] Brand names always start with an uppercase letter. Some brand names incorporate tall man letters in initial characters and may not be readily recognized as brand names. A double dagger follows all brand names on the ISMP list.



^{*} These drugs have been discontinued and are not marketed in the United States.

 $^{^{\}dagger}$ These drug names are also on the FDA list.

Drug Name With Tall Man Letters	Confused With
methazol AMIDE	meth IMA zole — met OL azone
meth lMA zole	methazol AMIDE — met OL azone
met OL azone	methazol AMIDE — meth IMA zole
metro NIDAZOLE	met FORMIN
metyra PONE	metyro SINE
metyro SINE	metyra PONE
mi FEPRIS tone	mi SOPROS tol
mig ALA stat [†]	mig LU stat [†]
mig LU stat [†]	mig ALA stat [†]
mi SOPROS tol	mi FEPRIS tone
mito MY cin	mito XANTRONE †
mito XANTRONE †	mito MY cin
Nex AVAR ‡	Nex IUM [‡]
Nex IUM ‡	Nex AVAR ‡
ni CAR dipine [†]	NIFE dipine [†] — ni MOD ipine
NIFE dipine [†]	ni CAR dipine [†] — ni MOD ipine
ni MOD ipine	ni CAR dipine [†] — NIFE dipine [†]
Novo LIN ‡	Novo LOG [‡]
Novo LOG ‡	Novo LIN ‡
OLANZ apine	QUE tiapine
OX carbazepine	car BAM azepine
oxy BUTY nin	oxy CODONE — Oxy CONTIN [‡] — oxy MOR phone
oxy CODONE	HYDRO codone — oxy BUTY nin — Oxy CONTIN ‡ — oxy MOR phone
Oxy CONTIN ‡	oxy BUTY nin — oxy CODONE — oxy MOR phone
oxy MOR phone	HYDRO morphone [†] — oxy BUTY nin — oxy CODONE — Oxy CONTIN
PACL itaxel	DOCE taxel
PAR oxetine	DUL oxetine — FLU oxetine
PAZOP anib	PONAT inib
PEME trexed	PRALA trexate
penicill AMINE	penicillin
PENT obarbital	PHEN obarbital
PHEN obarbital	PENT obarbital
PHYS ostigmine	py RID ostigmine
PONAT inib	PAZOP anib
PRALA trexate	PEME trexed
Pri LOSEC [‡]	PRO zac [‡]
PRO zac [‡]	Pri LOSEC [‡]

continued on page 6 >

[‡] Brand names always start with an uppercase letter. Some brand names incorporate tall man letters in initial characters and may not be readily recognized as brand names. A double dagger follows all brand names on the ISMP list.



^{*} These drugs have been discontinued and are not marketed in the United States.

 $^{^{\}dagger}$ These drug names are also on the FDA list.

Drug Name With Tall Man Letters	Confused With
py RID ostigmine	PHYS ostigmine
QUE tiapine	OLANZ apine
qui NID ine	qui NINE
qui NINE	qui NID ine
RABE prazole	ARIP iprazole
ra NITI dine*	ri MANTA dine
rif AMP in	rif AXIM in
rif AXIM in	rif AMP in
ri MANTA dine	ra NITI dine*
Risper DAL ‡	r OPINIR ole [†]
risperi DONE †	r OPINIR ole [†]
ri TUX imab	in FLIX imab
romi DEP sin	romi PLOS tim
romi PLOS tim	romi DEP sin
r OPINIR ole [†]	Risper DAL [‡] — risperi DONE [†]
ROP ivacaine	BUP ivacaine
Sand IMMUNE [‡]	Sando STATIN ‡
Sando STATIN [‡]	Sand IMMUNE [‡]
s AX agliptin	SIT agliptin
SIT agliptin	s AX agliptin — SUMA triptan
Solu- CORTEF [‡]	SOLU -Medrol [‡]
SOLU -Medrol [‡]	DEPO -Medrol* — Solu- CORTEF *
SORA fenib	SUNI tinib
SUF entanil	AL fentanil — fenta NYL
sulf ADIAZINE [†]	sulfa SALA zine
sulfa SALA zine	sulf ADIAZINE †
SUMA triptan	SITagliptin — ZOLMitriptan
SUNI tinib	SORA fenib
tia GAB ine	ti ZAN idine
ti ZAN idine	tia GAB ine
tra MAD ol [†]	tra ZOD one [†]
tra ZOD one [†]	tra MAD ol [†]
val ACY clovir	val GAN ciclovir
val GAN ciclovir	val ACY clovir
ZOLM itriptan	SUMA triptan
Zy PREXA ‡	Zyr TEC [‡]

^{*} These drugs have been discontinued and are not marketed in the United States.

[‡] Brand names always start with an uppercase letter. Some brand names incorporate tall man letters in initial characters and may not be readily recognized as brand names. A double dagger follows all brand names on the ISMP list.



 $^{^{\}dagger}$ These drug names are also on the FDA list.

References

- 1) DeHenau C, Becker MW, Bello NM, Liu S, Bix L. Tallman lettering as a strategy for differentiation in look-alike, sound-alike drug names: the role of familiarity in differentiating drug doppelgangers. Appl Ergon. 2016;52:77-84.
- 2) Filik R, Purdy K, Gale A, Gerrett D. Drug name confusion: evaluating the effectiveness of capital ("tall man") letters using eye movement data. Soc Sci Med. 2004;59(12):2597-601.
- 3) Filik R, Purdy K, Gale A, Gerrett D. Labeling of medicines and patient safety: evaluating methods of reducing drug name confusion. Hum Factors. 2006;48(1):39-47.
- 4) Grasha A. Cognitive systems perspective on human performance in the pharmacy: implications for accuracy, effectiveness, and job satisfaction Report No. 062100. National Association of Chain Drug Stores (NACDS); 2000.
- 5) Darker IT, Gerret D, Filik R, Purdy KJ, Gale AG. The influence of 'tall man' lettering on errors of visual perception in the recognition of written drug names. Ergonomics. 2011;54(1):21-33.
- 6) Or CKL, Chan AHS. Effects of text enhancements on the differentiation performance of orthographically similar drug names. Work. 2014;48(4):521-8.
- 7) Or CKL, Wang H. A comparison of the effects of different typographical methods on the recognizability of printed drug names. Drug Saf. 2014;37(5):351-9.
- 8) Filik R, Price J, Darker I, Gerrett D, Purdy K, Gale A. The influence of tall man lettering on drug name confusion: a laboratorybased investigation in the UK using younger and older adults and healthcare practitioners. Drug Saf. 2010;33(8):677-87.
- 9) Gabriele S. The role of typography in differentiating look-alike/ sound-alike drug names. Healthc Q. 2006; 9(Spec No):88-95.
- 10) Wang H, Tao D, Yan M. Effects of text enhancement on reduction of look-alike drug name confusion: a systematic review and meta-analysis. Qual Manag Health Care. 2021;30(4):233-43.

- 11) Chan AS, Muller RJ, Mancuso CE. Description of a tall-man lettering program for look-alike and sound-alike antineoplastic agents. Am J Health Syst Pharm. 2018;75(8):512-3.
- 12) Larmene-Beld KHM, Alting EK, Taxis K. A systematic literature review on strategies to avoid look-alike errors of labels. Eur J Clin Pharmacol. 2018;74(8):985-93.
- 13) Schell KL. Using enhanced text to facilitate recognition of drug names: evidence from two experimental studies. Appl Ergon. 2009;40(1):82-90.
- 14) Irwin A, Mearns K, Watson M, Urguhart J. The effect of proximity, tall man lettering, and time pressure on accurate visual perception of drug names. Hum Factors. 2013;55(2):253-66.
- 15) Zhong W, Feinstein JA, Patel NS, Dai D, Feudtner C. Tall man lettering and potential prescription errors: a time series analysis of 42 children's hospitals in the USA over 9 years. BMJ Qual Saf. 2016;25(4):233-40.
- 16) Lambert BL, Schroeder SR, Galanter WL. Does tall man lettering prevent drug name confusion errors? Incomplete and conflicting evidence suggest need for definitive study. BMJ Qual Saf. 2016;25(4):213-7.
- 17) Leape LL, Berwick DM, Bates DW. What practices will most improve safety? Evidence-based medicine meets patient safety. JAMA. 2002;288(4):501-7.
- 18) Position statement on improving the safety of international non-proprietary names of medicines (INNs). Horsham (PA): International Medication Safety Network; November 2011.
- 19) Gerrett D, Gale AG, Darker IT, Filik R, Purdy KJ. Tall man lettering. Final report of the use of tall man lettering to minimise selection errors of medicine names in computer prescribing and dispensing systems. Loughborough University Enterprises Ltd; 2009.

